Immunology and Microbiology
Cytotoxic T-Cell
100%
T Cell
90%
CD4
76%
Regulatory T Cell
74%
Dendritic Cell
72%
Lymph Node
63%
Graft-Versus-Host Disease
49%
T Cell Receptor
46%
Fibroblast
45%
Chemokine
43%
T-Helper Cell
42%
Myeloid-Derived Suppressor Cell
41%
Chemokine Receptor
40%
Macrophage
38%
Peptides
30%
Osteoblast
27%
Cell Population
25%
Antigen Specificity
25%
Cytotoxic T Cell
24%
Immunosuppressive Drug
24%
Osteoclast
24%
Allogeneic Hematopoietic Stem Cell Transplantation
23%
Colitis
23%
CD25
22%
Memory T Cell
21%
B Cell
21%
Cell Migration
21%
Lymphocyte
20%
Hematopoiesis
19%
Immune Response
18%
Cell Cycle
18%
CD8
18%
Venule
17%
Graft Versus Tumor Effect
17%
Precursor
17%
Immunotherapy
16%
Chemokine Receptor CXCR3
16%
Methicillin-Resistant Staphylococcus Aureus
16%
CD4 Antibody
16%
Myeloid
16%
Homeostasis
15%
CCR2
14%
Viral Disease
14%
Airway
14%
Lupus Erythematosus
14%
Murine
13%
Cell Clone
13%
CCR5
13%
Chronic Graft Versus Host Disease
13%
MHC Class I
12%
Keyphrases
CD8+ T Cells
72%
Tumor
59%
Dendritic Cells
55%
Pulmonary Fibrosis
54%
Olfactory Sensory Neuron
52%
Graft-versus-host Disease (GvHD)
50%
Fibroblasts
46%
Lymph Node
42%
Regulatory T (Treg) Cells
42%
Antitumor Effect
40%
Myeloid-derived Suppressor Cells
37%
Cigarette Smoking
36%
Chemokines
36%
Anti-CD4
35%
Tumor-bearing Mice
33%
T Cells
31%
Treg
31%
Olfactory Epithelium
30%
Murine Model
28%
Lung
28%
C-C Chemokine Receptor Type 5 (CCR5)
25%
Chemokine Receptor
25%
Spleen
24%
Cytotoxic T Lymphocytes
24%
Osteoblast
23%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
23%
CCR7
21%
CD4+ T Cells
20%
COVID-19
20%
Activated Fibroblasts
19%
Olfactory Dysfunction
19%
Osteoclast
19%
Memory T Cells
18%
CD4+
18%
Anti-CD4 Antibody
18%
Foxp3+ Regulatory T Cells
18%
T-cell Receptor Repertoire
18%
Tumor Growth
17%
Silica
17%
Gene-deficient Mice
17%
Combined Treatment
17%
High Endothelial Venules
17%
Graft-versus-leukemia Effect
17%
FoxP3+
16%
Fibroblast Activation
16%
Tissue Cells
16%
Inflammation
16%
Regulatory T Cells
16%
Tumor-infiltrating T Cells
16%
Antibody Treatment
16%